This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Pariet (Japan), rabeprazole sodium, E3810
Description: Aciphex, known as Pariet in Europe, is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
Deal Structure: In April 1997, Eisai and Janssen Pharmaceutica (an affiliate of Johnson & Johnson) announced a strategic alliance for rabeprazole. Under this agreement, Eisai and Janssen will copromote rabeprazole in the U.S., U.K., Germany, and France. Janssen will have an exclusive license to market rabeprazole in other territories excluding Japan and other countries in Asia; Italy; Spain; Belgium; Holland. In Italy and Spain, Janssen will have a semiexclusive license. In Spain, Eisai will retain the right to copromote or comarket rabeprazole. Eisai will receive milestone payments from Janssen according to this agreement.
Historical sales listed in BMT for Aciphex only represent those announced by Johnson & Johnson (and not Eisai).
Eisai and FSC Therapeutics
In June 2014, FSC Therapeutics announced that the Company has entered into a transaction with Eisai to acquire exclusive U.S. marketing rights for AcipHex Sprinkle (rabeprazole sodium), Delayed-Release Capsules, 5 mg and...See full deal structure in Biomedtracker
Partners: EA Pharma Co., Ltd. Flamel Technologies
Additional information available to subscribers only: